Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial-Reference-Cited by-同舟云学术

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Published:2012-11 Issue:9856 Volume:380 Page:1819-1828
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Cohen Jeffrey A,Coles Alasdair J,Arnold Douglas L,Confavreux Christian,Fox Edward J,Hartung Hans-Peter,Havrdova Eva,Selmaj Krzysztof W,Weiner Howard L,Fisher Elizabeth,Brinar Vesna V,Giovannoni Gavin,Stojanovic Miroslav,Ertik Bella I,Lake Stephen L,Margolin David H,Panzara Michael A,Compston D Alastair S

Publisher

Elsevier BV

Subject

General Medicine

Reference35 articles.

1. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis;Cox;Eur J Immunol,2005

2. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H);Jones;J Clin Invest,2009

3. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis;Thompson;J Clin Immunol,2010

4. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis;Moreau;Lancet,1994

5. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis;Coles;Ann Neurol,1999

Cited by 1026 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis treatments a review of current biomedical engineering approaches;Biomaterials;2025-02

2. A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network;Multiple Sclerosis and Related Disorders;2024-11

3. Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study;Multiple Sclerosis and Related Disorders;2024-10

4. MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial;Trials;2024-09-11

5. The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: a five-year prospective mono-center study;Multiple Sclerosis and Related Disorders;2024-09